Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will publish any of the pre-clinical data, study reports or assessments made by the Medicines and Healthcare products Regulatory Agency (MHRA) that the MHRA’s Chief Safety Officer relied upon when quoted in a GB News online article, dated 27 March 2026, that the available evidence does not support an association between COVID-19 vaccination and an increased risk of cancer.

The GB News article in question, dated 27 March 2026, does not appear to reference any specific pre-clinical data, safety reports, or assessments. As part of its statutory functions, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for continuously monitoring all medicines, including vaccines, post-authorisation to ensure their benefits continue to outweigh any risks. This continuous, proactive safety surveillance draws upon a wide range of sources of safety data, including analysis of large healthcare datasets, review of international safety data, emerging research, data provided by academia, Yellow Card reports, and ongoing review by independent scientific experts.

There are currently no plans to publish any additional pre-clinical data, study reports, or assessments, beyond what is routinely published. For suspected side effects being reported for medicines and vaccines, the MHRA publishes Yellow card data which can be accessed at the following link:

https://yellowcard.mhra.gov.uk/idaps

The MHRA also published a summary of Yellow Card reporting, which can be accessed at the following link:

https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting